Activation of GPR55 Receptors Exacerbates oxLDL-Induced Lipid Accumulation and Inflammatory Responses, while Reducing Cholesterol Efflux from Human Macrophages

The G protein-coupled receptor GPR55 has been proposed as a new cannabinoid receptor associated with bone remodelling, nervous system excitability, vascular homeostasis as well as in several pathophysiological conditions including obesity and cancer. However, its physiological role and underlying mechanism remain unclear. In the present work, we demonstrate for the first time its presence in human macrophages and its increased expression in ox-LDL-induced foam cells. In addition, pharmacological activation of GPR55 by its selective agonist O-1602 increased CD36- and SRB-I-mediated lipid accumulation and blocked cholesterol efflux by downregulating ATP-binding cassette (ABC) transporters ABCA1 and ABCG1, as well as enhanced cytokine- and pro-metalloprotease-9 (pro-MMP-9)-induced proinflammatory responses in foam cells. Treatment with cannabidiol, a selective antagonist of GPR55, counteracted these pro-atherogenic and proinflammatory O-1602-mediated effects. Our data suggest that GPR55 could play deleterious role in ox-LDL-induced foam cells and could be a novel pharmacological target to manage atherosclerosis and other related cardiovascular diseases.

[1]  M. De Bardi,et al.  The differential characterization of GPR55 receptor in human peripheral blood reveals a distinctive expression in monocytes and NK cells and a proinflammatory role in these innate cells. , 2015, International immunology.

[2]  P. Aukrust,et al.  Interleukin-10 increases reverse cholesterol transport in macrophages through its bidirectional interaction with liver X receptor α. , 2014, Biochemical and biophysical research communications.

[3]  A. McAinch,et al.  A potential role for GPR55 in the regulation of energy homeostasis. , 2014, Drug discovery today.

[4]  F. Fezza,et al.  Detailed characterization of the endocannabinoid system in human macrophages and foam cells, and anti-inflammatory role of type-2 cannabinoid receptor. , 2014, Atherosclerosis.

[5]  P. Flatt,et al.  Evaluation of the insulin releasing and antihyperglycaemic activities of GPR55 lipid agonists using clonal beta‐cells, isolated pancreatic islets and mice , 2013, British journal of pharmacology.

[6]  K. Mackie,et al.  A role for O-1602 and G protein-coupled receptor GPR55 in the control of colonic motility in mice , 2013, Neuropharmacology.

[7]  M. Waldhoer,et al.  A Selective Antagonist Reveals a Potential Role of G Protein–Coupled Receptor 55 in Platelet and Endothelial Cell Function , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[8]  Albina Arjuman,et al.  Effect of IL-10 on LOX-1 expression, signalling and functional activity: An atheroprotective response , 2013, Diabetes & vascular disease research.

[9]  D. Centonze,et al.  Distinct modulation of human myeloid and plasmacytoid dendritic cells by anandamide in multiple sclerosis , 2013, Annals of neurology.

[10]  D. Rusakov,et al.  Cannabinoid- and lysophosphatidylinositol-sensitive receptor GPR55 boosts neurotransmitter release at central synapses , 2013, Proceedings of the National Academy of Sciences.

[11]  S. Steffens,et al.  Targeting cannabinoid receptor CB2 in cardiovascular disorders: promises and controversies , 2012, British journal of pharmacology.

[12]  P. Ricciardi-Castagnoli,et al.  NFAT control of innate immunity. , 2012, Blood.

[13]  M. Malagón,et al.  The atypical cannabinoid O‐1602 stimulates food intake and adiposity in rats , 2012, Diabetes, obesity & metabolism.

[14]  J. Moreno-Navarrete,et al.  The l-α-Lysophosphatidylinositol/GPR55 System and Its Potential Role in Human Obesity , 2012, Diabetes.

[15]  S. Zimmer,et al.  Atheroprotection via cannabinoid receptor-2 is mediated by circulating and vascular cells in vivo. , 2011, Journal of molecular and cellular cardiology.

[16]  S. Romero-Zerbo,et al.  A role for the putative cannabinoid receptor GPR55 in the islets of Langerhans. , 2011, The Journal of endocrinology.

[17]  F. Basile,et al.  Endocannabinoids inhibit release of nerve growth factor by inflammation-activated mast cells. , 2011, Biochemical pharmacology.

[18]  M. Caron,et al.  Screening for Selective Ligands for GPR55 - Antagonists , 2011 .

[19]  H. van Eenennaam,et al.  Cannabinoid Receptor 2 Deficiency in Haematopoietic cells Aggravates Early Atherosclerosis in LDL Receptor Deficient Mice , 2011, The open cardiovascular medicine journal.

[20]  M. Maccarrone,et al.  Endomorphin-1 prevents lipid accumulation via CD36 down-regulation and modulates cytokines release from human lipid-laden macrophages , 2011, Peptides.

[21]  D. Thewke,et al.  Cannabinoid receptor type 2 (CB2) deficiency alters atherosclerotic lesion formation in hyperlipidemic Ldlr-null mice. , 2010, Atherosclerosis.

[22]  W. Graier,et al.  GPR55-dependent and -independent ion signalling in response to lysophosphatidylinositol in endothelial cells , 2010, British journal of pharmacology.

[23]  J. Groopman,et al.  Endocannabinoid‐like N‐arachidonoyl serine is a novel pro‐angiogenic mediator , 2010, British journal of pharmacology.

[24]  M. Abood,et al.  Pharmacological characterization of GPR55, a putative cannabinoid receptor. , 2010, Pharmacology & therapeutics.

[25]  R. de Caterina,et al.  Statins inhibit cyclooxygenase-2 and matrix metalloproteinase-9 in human endothelial cells: anti-angiogenic actions possibly contributing to plaque stability. , 2010, Cardiovascular research.

[26]  G. Bernardi,et al.  Anandamide Suppresses Proliferation and Cytokine Release from Primary Human T-Lymphocytes Mainly via CB2 Receptors , 2010, PloS one.

[27]  K. Tan,et al.  ABCG1 mediated oxidized LDL-derived oxysterol efflux from macrophages. , 2009, Biochemical and biophysical research communications.

[28]  K. Mackie,et al.  Regulation of MAP Kinase–Directed Mitogenic and Protein Kinase B–Mediated Signaling by Cannabinoid Receptor Type 1 in Skeletal Muscle Cells , 2009, Diabetes.

[29]  K. Mackie,et al.  The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo , 2009, Proceedings of the National Academy of Sciences.

[30]  Jerzy Bełtowski,et al.  Adverse effects of statins - mechanisms and consequences. , 2009, Current drug safety.

[31]  R. Ross.  The enigmatic pharmacology of GPR55. , 2009, Trends in pharmacological sciences.

[32]  A. Irving,et al.  The GPR55 ligand L‐α‐lysophosphatidylinositol promotes RhoA‐dependent Ca2+ signaling and NFAT activation , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[33]  B. Staels,et al.  Rimonabant, a Selective Cannabinoid CB1 Receptor Antagonist, Inhibits Atherosclerosis in LDL Receptor–Deficient Mice , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[34]  A. Modesti,et al.  Endomorphin-1 Inhibits the Activation and the Development of a Hyporesponsive-like Phenotype in Lipopolysaccharide-Stimulated THP-1 Monocytes , 2008, International journal of immunopathology and pharmacology.

[35]  I. Chessell,et al.  The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain , 2008, PAIN.

[36]  V. Izzi,et al.  Brain Natriuretic Peptide (BNP) regulates the production of inflammatory mediators in human THP-1 macrophages , 2008, Regulatory Peptides.

[37]  Markus Waldeck-Weiermair,et al.  Integrin clustering enables anandamide-induced Ca2+ signaling in endothelial cells via GPR55 by protection against CB1-receptor-triggered repression , 2008, Journal of Cell Science.

[38]  F. Mach,et al.  The Role of the Endocannabinoid System in Atherosclerosis , 2008, Journal of neuroendocrinology.

[39]  Juliette Martin,et al.  CD36 and macrophages in atherosclerosis. , 2007, Cardiovascular research.

[40]  A. Tall,et al.  Cholesterol-induced Apoptotic Macrophages Elicit an Inflammatory Response in Phagocytes, Which Is Partially Attenuated by the Mer Receptor* , 2006, Journal of Biological Chemistry.

[41]  J. Després,et al.  Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. , 2005, The New England journal of medicine.

[42]  H. Brewer,et al.  The human ABCG1 gene: identification of LXR response elements that modulate expression in macrophages and liver Published, JLR Papers in Press, July 16, 2005. DOI 10.1194/jlr.M500080-JLR200 , 2005, Journal of Lipid Research.

[43]  M. Bennett,et al.  Tumor Necrosis Factor-&agr; Promotes Macrophage-Induced Vascular Smooth Muscle Cell Apoptosis by Direct and Autocrine Mechanisms , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[44]  P. Libby.  Inflammation in atherosclerosis , 2002, Nature.

[45]  Seth M. Klein,et al.  Scavenger receptor class B type I affects cholesterol homeostasis by magnifying cholesterol flux between cells and HDL. , 2001, Journal of lipid research.

[46]  Y. Pak,et al.  Role of endocytosis in the transactivation of nuclear factor-κB by oxidized low-density lipoprotein , 2000 .

[47]  A. Tall,et al.  Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. , 2000, The Journal of biological chemistry.

[48]  M. Seishima,et al.  Disruption of tumor necrosis factor-alpha gene diminishes the development of atherosclerosis in ApoE-deficient mice. , 2000, Atherosclerosis.

[49]  R. Evans,et al.  Oxidized LDL Regulates Macrophage Gene Expression through Ligand Activation of PPARγ , 1998, Cell.

[50]  R. Evans,et al.  PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL , 1998, Cell.

[51]  M. Feldmann,et al.  Beneficial effects of tumour necrosis factor‐alpha (TNF‐α) blockade in rheumatoid arthritis (RA) , 1995, Clinical and experimental immunology.

[52]  E. Kostenis,et al.  Gpr55 Regulates Cannabinoid 2 Receptor-mediated Responses in Human Neutrophils Ukpmc Funders Group Author Manuscript Introduction , 2022 .

[53]  P. Pacher.  Cannabinoid CB1 receptor antagonists for atherosclerosis and cardiometabolic disorders: new hopes, old concerns? , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[54]  C. Palumbo,et al.  Differential effects of malignant mesothelioma cells on THP-1 monocytes and macrophages. , 2009, International journal of oncology.

[55]  D. McHugh,et al.  Endogenous cannabinoids and neutrophil chemotaxis. , 2009, Vitamins and hormones.

[56]  Y. Pak,et al.  Role of endocytosis in the transactivation of nuclear factor-kappaB by oxidized low-density lipoprotein. , 2000, Biochemical Journal.

[57]  R. Evans,et al.  PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. , 1998, Cell.

[58]  Robert Lipsky,et al.  The carboxyl-terminal cytoplasmic domain of CD36 is required for oxidized low-density lipoprotein modulation of NF-kappaB activity by tumor necrosis factor-alpha. , 1997, Receptors & signal transduction.